Raman spectroscopy in lung cancer diagnostics: Can an in vivo setup compete with ex vivo applications?
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy · 2024
DOI: 10.1016/j.saa.2024.124770 ↗Kurz gefasst
Fachartikel in der Zeitschrift Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2024. Verfasst von Markéta Fousková und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Analytical Chemistry, University of Chemistry and Technology, Prague, Technická 5, 166 28, Prague 6, Czech Republic. Hauptthemen laut MEDLINE: Spectrum Analysis, Raman, Lung Neoplasms, Principal Component Analysis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: Ministry of Health of the Czech Republic, Všeobecná Fakultní Nemocnice v Praze.
Abstract (Originalsprache)
Lung carcinoma remains the leading cause of cancer death worldwide. The tactic to change this unfortunate rate may be a timely and rapid diagnostic, which may in many cases improve patient prognosis. In our study, we focus on the comparison of two novel methods of rapid lung carcinoma diagnostics, label-free in vivo and ex vivo Raman spectroscopy of the epithelial tissue, and assess their feasibility in clinical practice. As these techniques are sensitive not only to the basic molecular composition of the analyzed sample but also to the secondary structure of large biomolecules, such as tissue proteins, they represent suitable candidate methods for epithelial cancer diagnostics. During routine bronchoscopy, we collected 78 in vivo Raman spectra of normal and cancerous lung tissue and 37 samples of endobronchial pathologies, which were subsequently analyzed ex vivo. Using machine learning techniques, namely principal component analysis (PCA) and support vector machines (SVM), we were able to reach 87.2% (95% CI, 79.8-94.6%) and 100.0% (95% CI, 92.1-100.0%) of diagnostic accuracy for in vivo and ex vivo setup, respectively. Although the ex vivo approach provided superior results, the rapidity of in vivo Raman spectroscopy might become unmatchable in the acceleration of the diagnostic process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Analytical Chemistry, University of Chemistry and Technology, Prague, Technická 5, 166 28, Prague 6, Czech Republic.
- 1st Clinic of Tuberculosis and Respiratory Diseases, 1st Faculty of Medicine, Charles University Prague and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic.
- Department of Analytical Chemistry, University of Chemistry and Technology, Prague, Technická 5, 166 28, Prague 6, Czech Republic. Electronic address: Vladimir.Setnicka@vscht.cz.
Förderung
- Ministry of Health of the Czech Republic
- Všeobecná Fakultní Nemocnice v Praze
Zitieren
APA
Fousková, M., Habartová, L., Vališ, J., Nahodilová, M., Vaňková, A., Synytsya, A., Šestáková, Z., Votruba, J., & Setnička, V. (2024). Raman spectroscopy in lung cancer diagnostics: Can an in vivo setup compete with ex vivo applications?. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. https://doi.org/10.1016/j.saa.2024.124770
Vancouver
Fousková M, Habartová L, Vališ J, Nahodilová M, Vaňková A, Synytsya A, et al. Raman spectroscopy in lung cancer diagnostics: Can an in vivo setup compete with ex vivo applications?. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2024. doi:10.1016/j.saa.2024.124770
BibTeX
@article{Fouskov2024,
author = {Fousková, Markéta and Habartová, Lucie and Vališ, Jan and Nahodilová, Magdaléna and Vaňková, Aneta and Synytsya, Alla and Šestáková, Zuzana and Votruba, Jiří and Setnička, Vladimír},
title = {Raman spectroscopy in lung cancer diagnostics: Can an in vivo setup compete with ex vivo applications?},
journal = {Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy},
year = {2024},
doi = {10.1016/j.saa.2024.124770}
}
EUVIMED